[11C]meta-hydroxyephedrine PET evaluation in experimental pulmonary arterial hypertension: Effects of carvedilol of right ventricular sympathetic function

[1] D’Alonzo GE(1991)Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 343-349

[2] Barst RJ(2009)The sympathetic nervous system in heart failure J Am Coll Cardiol 54 1747-1762

[3] Ayres SM(2010)Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension Am J Respir Crit Care Med 181 1269-1275

[4] Bergofsky EH(1996)The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group N Engl J Med 334 1349-1355

[5] Brundage BH(2016)2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur Heart J 37 67-119

[6] Detre KM(2009)Effects of a pure α/β-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats Circ J 73 2337-2341

[7] Fishman AP(2010)Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats Am J Respir Crit Care Med 182 652-660

[8] Goldring RM(2006)Deleterious effects of β-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension Gastroenterology 130 120-126

[9] Groves BM(2016)Bisoprolol in idiopathic pulmonary arterial hypertension: An explorative study Eur Respir J 48 787-796

[10] Kernis JT(2016)The adrenergic nervous system as a therapeutic target in pulmonary arterial hypertension: A cautionary tale Eur Respir J 48 617-618

[1] D’Alonzo GE(1991)Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 343-349

[2] Barst RJ(2009)The sympathetic nervous system in heart failure J Am Coll Cardiol 54 1747-1762

[3] Ayres SM(2010)Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension Am J Respir Crit Care Med 181 1269-1275

[4] Bergofsky EH(1996)The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group N Engl J Med 334 1349-1355

[5] Brundage BH(2016)2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur Heart J 37 67-119

[6] Detre KM(2009)Effects of a pure α/β-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats Circ J 73 2337-2341

[7] Fishman AP(2010)Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats Am J Respir Crit Care Med 182 652-660

[8] Goldring RM(2006)Deleterious effects of β-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension Gastroenterology 130 120-126

[9] Groves BM(2016)Bisoprolol in idiopathic pulmonary arterial hypertension: An explorative study Eur Respir J 48 787-796

[10] Kernis JT(2016)The adrenergic nervous system as a therapeutic target in pulmonary arterial hypertension: A cautionary tale Eur Respir J 48 617-618